Windtree Therapeutics, Inc. (NasdaqCM: WINT) will present a corporate update, including recent positive data from its Phase 2b SEISMiC Extension Study of istaroxime, at the ThinkEquity Conference on October 30th. Craig Fraser, Chairman and CEO, will deliver the presentation, focusing on the potential of istaroxime in treating heart failure associated with early cardiogenic shock.
Istaroxime: A Novel Dual-Mechanism Therapy
Istaroxime represents a first-in-class therapeutic approach, designed to enhance both systolic and diastolic cardiac function. Its dual mechanism involves increasing myocardial contractility through the inhibition of Na+/K+-ATPase and facilitating myocardial relaxation by activating the SERCA2a calcium pump. This unique combination aims to improve cardiac performance without the adverse effects of increased heart rate or cardiac rhythm disturbances.
Clinical Evidence and Potential Benefits
Data from multiple Phase 2 studies have demonstrated that intravenous infusion of istaroxime significantly improves cardiac function and blood pressure in patients with early cardiogenic shock or acute decompensated heart failure. These findings suggest that istaroxime could address a critical unmet need in managing acute heart failure syndromes, where rapid and effective hemodynamic support is essential.
Windtree Therapeutics: Advancing Therapies for Critical Conditions
Windtree Therapeutics is focused on developing innovative therapies for critical conditions and diseases. Their portfolio includes istaroxime, a Phase 2 candidate targeting acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, and preclinical precision aPKCi inhibitors for oncology applications. The company also employs a licensing business model with existing partnership out-licenses.
